



ANNUAL
REPORT
2024



www.omeract.org

Table of Contents

About OMERACT	3
A Message From The Management Group	4
OMERACT Community Overview	5
Leadership And Committees	6
Progress and Achievements: Updates from Committees—	8
Working Group Co-Chairs	13
Working Group Support Summary	14
Working Groups' Progress	15
Publications	18
OMERACT Priorities for 2025	19
2024 Expenditure Summary	20
OMERACT 2025 Conference Budget	20
2024 Sponsor Support	21
OMERACT 2025 Save the Date	22



About OMERACT

Founded over 30 years ago, OMERACT is a not-for-profit organization whose mission is to improve the quality and relevance of clinical trials by developing consensus-driven Core Outcome Sets (COS) that address the needs of all collaborators, including patients, clinicians, researchers, and regulators.

Central to OMERACT's work is its rigorous methodology, the OMERACT Filter, which ensures that outcomes are truthful, discriminative, and feasible. By fostering collaboration and consensus-building among diverse stakeholders, OMERACT ensures that outcomes reflect the lived experiences of patients while meeting the scientific and regulatory standards required for adoption in clinical trials. Through its global Working Groups, OMERACT supports the development of COS by identifying patient- and disease-relevant domains and the corresponding measurement instruments for use in clinical trials, including those supporting regulatory approval of new treatments.

OMERACT's network includes over 1,000 participants, with more than 200 Patient Research Partners (PRPs) representing 41 countries across six continents.

A cornerstone of OMERACT's activities is its biennial conference, where collaborators convene to address complex challenges in Core Outcome Set research. These events serve as a platform for advancing methodological innovation, exploring new areas such as composite outcomes, and sharing knowledge that strengthens the field of rheumatology.

As a leader in patient-engaged outcomes research, OMERACT has achieved significant milestones, including the development of Core Outcome Sets adopted in clinical trials worldwide.

Looking ahead, OMERACT remains committed to fostering sustainable partnerships, advancing inclusivity, and addressing emerging challenges in outcomes research. With a vision for continuous innovation and collaboration, OMERACT aims to sustain its legacy as a driving force in improving health outcomes in rheumatology and beyond.

Message from the Management Group



Peter Tugwell, MSc, MD, FRCPC
Ottawa, Canada
Chair



Dorcas Beaton, BScOT, PhD
Toronto, Canada
Chair - Methods



Philip Conaghan, MB BS, PhD,
FRACP, FRCP
Leeds, UK
Deputy Chair



Catherine Hofstetter
Toronto, Canada
Chair - Patient Research
Partner Engagement



Lee Simon, MD, FACP, MACR
Boston, USA
Chair - Finance

As 2024 draws to a close, we reflect on a year filled with remarkable progress and meaningful collaborations within the OMERACT community. Together, we have continued to advance our mission of improving outcomes research through the development of Core Outcome Sets, ensuring that the voices of all collaborators—particularly patients—are integral to our work.

This year has been one of both challenges and achievements. From hosting virtual endorsement sessions for our working groups to refining our methodologies for instrument selection and domain generation, the contributions from our Working Groups and Patient Research Partners (PRPs) have been invaluable. The dedication and passion within our community have been evident in every step we have taken together.

Looking ahead to 2025, we are excited to reconvene in at OMERACT 2025. This gathering will provide an opportunity to reflect on the progress made since our last in-person meeting and chart the path forward for OMERACT's future. Key discussions will include the sustainability of OMERACT beyond 2027, further enhancements to our PRP engagement strategies, and continued methodological advancements in Instrument Selection and Composite Outcome Measures.

As we plan for the future, we remain steadfast in our commitment to the core values that have made OMERACT a leader in outcomes research. We are grateful for the contributions of every OMERACTer in this community—researchers, clinicians, industry representatives, regulators, and PRPs. It is your shared dedication that propels our work forward.


Thank you for your unwavering support and participation in 2024 and look forward to another productive and impactful year in 2025.

Dorcas Beaton, Phil Conaghan, Catherine Hofstetter, Lee Simon & Peter Tugwell
OMERACT Management Team

OMERACT Community Overview

In 2024, OMERACT's global community continued to grow, with contributors from across six continents. This year, our network included 1,079 collaborators, comprising 630 principal investigators, 215 Patient Research Partners (PRPs), 98 providers, and representatives from policymaking, product development, and other fields.

Our collaborators represented regions worldwide. This diverse representation underscores OMERACT's commitment to inclusivity, equity, and a multidisciplinary approach in advancing Core Outcome Sets research.



OMERACTers by Collaborator Group

Patient Research Partners and Carers
19.9%



All Other Collaborator Groups
80.1%

All Other Collaborator Group

Product Makers

3.1%


Providers

11.3%

Other
12.5%

Principal investigators

73%



Leadership & Committees

MANAGEMENT GROUP



Chair

Dr. Peter Tugwell

Deputy - Chair

Dr. Philip Conaghan

Chair - Finance

Dr. Lee Simon

Chair - Methods

Dr. Dorcas Beaton

Chair - Patient Research Partner Engagement

Catherine Hofstetter

PATIENT RESEARCH PARTNER SUPPORT TEAM



Chair

Catherine Hofstetter

MEMBERS

Mary Cowern

Ingrid de Groot

Ben Horgan

Maya Desai

BUSINESS ADVISORY COMMITTEE



Co - Chair

Dr. Lee Simon

Co - Chair

Dr. Vibeke Strand

TECHNICAL ADVISORY GROUP



Chair

Dr. Dorcas Beaton

Co - Chair

Dr. Clifton "Bing" Bingham

Co - Chair

Dr. George Wells

MEMBERS

Dr. Annelies Boonen

Dr. Catherine Hill

Dr. Alexa Meara

Dr. Wen-Hung Chen

Catherine Hofstetter

Dr. Ioannis Parodis

Dr. Ernest Choy

Ben Horgan

Dr. Didem Saygin

Dr. Robin Christensen

Dr. Helen Keen

Dr. Zahi Touma

Dr. Andrea Doria

Dr. Katy Leung

Dr. Peter Tugwell

Dr. Glen Hazelwood

Leadership & Committees Continued



EQUITY, DIVERSITY, AND INCLUSION (EDI) STRATEGIC ADVISORY WORKING GROUP

Co - Chair

Dr. Jennifer Barton

Co - Chair

Dr. Francis Guillemin

Co - Chair

Grayson Schultz

Co - Chair

Dr. Grace Wright



STRATEGIC ADVISORY GROUP

Co - Chair

Dr. Maria Antonietta D'Agostino

Co - Chair

Dr. Lyn March

Co - Chair

Dr. Peter Tugwell

MEMBERS

Dr. Robin Christensen

Ingrid de Groot

Dr. Francis Guillemin

Dr. Catherine Hill

Ben Horgan

Dr. Peter Merkel


Dr. Mikkel Ostergaard

Dr. Bethan Richards

Grayson Schultz

Dr. Heidi Siddle

Dr. Vibeke Strand



OMERACT FELLOWS PROGRAM

Co-Chair

Dr. Caitlin Jones

Co-Chair

Dr. Suzanne Verstappen



OMERACT EMERGING LEADERS PROGRAM

Co-Chair

Dr. Bethan Richards

Co-Chair

Dr. Heidi Siddle

Co-Chair

Dr. Peter Tugwell

Progress and Achievements: Updates from Committees

Patient Research Partner Support Team



The OMERACT PRP Support Team fosters meaningful integration of Patient Research Partners (PRPs) throughout OMERACT by fostering engagement, enhancing communication, and ensuring diverse PRP perspectives are represented, while developing educational resources and advocating for patient-centred research.



Achievements 2024

- Revised the Conference Planning Checklist to better support participants with disabilities or mobility challenges, ensuring that OMERACT events are accessible to all.
- Reviewed and expanded the Glossary/List of Acronyms, providing essential updates to improve clarity and ensure that all participants, including PRPs, can engage effectively in discussions.
- Developed and launched a new bursary application process, resulting in 16 PRPs receiving financial support to attend OMERACT 2025 in Barcelona, Spain. This milestone underscores OMERACT's commitment to reducing financial barriers and enabling diverse global participation.
- Strengthening Community and Preparation:
 - Initiated "Meet and Greet" sessions for PRPs attending OMERACT 2025, fostering connections and preparing participants through sessions held in June, October, and December 2024.
 - Assigned "Buddies" to provide individualized support and mentorship to PRPs.
 - Established a WhatsApp group for the PRP Class of 2025, facilitating ongoing communication and collaboration.
- Continued to promote the PRP Directory, enabling new and returning PRPs to build networks and access valuable resources.
- Finalized Chapter 3 of the OMERACT Handbook: Patient Research Partner Engagement, a foundational resource to support PRPs and researchers and ensure meaningful engagement throughout the OMERACT process.
- Represented the PRP network at the American College of Rheumatology (ACR) conference in Washington, D.C., showcasing the critical role of PRPs in shaping rheumatology research.
- Engaged with the leaders of the Fellows program to strengthen alignment and opportunities for PRPs, emphasizing collaboration across OMERACT initiatives.



Priorities 2025

- **Skills Matrix:** Identify and leverage the unique expertise of PRPs to maximize their contributions and provide targeted growth opportunities.
- **"Meet and Greets":** Strengthen community-building and peer support by continuing regular sessions with PRPs preparing for OMERACT 2025.
- **Tailored PRP Program:** Design a structured program to empower PRPs with knowledge, leadership opportunities, and meaningful involvement at OMERACT 2025.
- **Collaboration with Leadership Programs:** Foster connections with Fellows, Emerging Leaders, and New OMERACTers to promote cross-functional mentorship and inclusivity.
- **Enhanced Education:** Expand OMERACT-ED materials in collaboration with methodologists to equip PRPs with essential knowledge and tools.



MEET the
PRP
SUPPORT
TEAM



Catherine Hofstetter, Chair
Toronto, Canada



Mary Cowern
South Wales, UK



Ingrid de Groot
The Netherlands



Maya Desai
Toronto, Canada



Ben Horgan
Australia

Technical Advisory Group



The OMERACT Technical Advisory Group (TAG) provides expert guidance in Core Outcome Set Development methodology, supporting OMERACT Working Groups through rigorous reviews and constructive feedback to ensure alignment with OMERACT standards. By advancing methodological excellence, the TAG upholds the integrity and quality of outcome measurement in rheumatology, contributing to OMERACT's mission to enhance outcome measurement in rheumatic diseases.



Achievements 2024

- **Progress in Instrument Selection:** Conducted comprehensive domain match and feasibility assessments for foundational domains (Pain Interference, Pain Intensity, Fatigue, and Physical Function). Systematic review of PROMIS instruments resulted in 170 articles selected for evaluating measurement properties, with patient research partner (PRP) feedback integrated throughout. Finalized protocols for the inclusion of PROMIS instruments, preparing for their ratification at OMERACT 2025.
- **Strengthened Collaboration with Working Groups:** TAG members actively supported working groups by reviewing study designs, domain generation processes, and instrument selection methods.
- **Integration of Methodological Advancements:** Supported the release of PRISMA-COSMIN guidelines and began adapting these into OMERACT processes.
- **Leadership and Succession Planning:** Initiated the search for a new Methods Chair, ensuring sustained leadership in advancing OMERACT methodologies post-2025.



Priorities 2025

- **Completion and Ratification of Foundational Domains:** Finalize and present the PROMIS instruments for Pain Interference, Pain Intensity, Fatigue, and Physical Function for ratification at OMERACT 2025.
- **Evaluation of Composite Outcome Measures:** Finalize the protocol for assessing composite measures (CDAI and SDAI) using the OMERACT Composite Methodology Filter. Host interactive workshops at OMERACT 2025 to gather real-time feedback and refine the approach.
- **Strengthening Methodological Leadership:** Prepare for a seamless transition in leadership with the appointment of a new Methods Chair.
- **Facilitating Impactful Discussions at OMERACT 2025:** Host workshops and collaborative sessions to address challenges in instrument selection, composite measures, and clinical trial discrimination. Use OMERACT 2025 as a platform to gather consensus and refine methodologies based on participant feedback.



OMERACT Equity, Diversity, and Inclusion (EDI) Strategic Advisory Working Group



The OMERACT Equity, Diversity, and Inclusion (EDI) Strategic Advisory Working Group serves a dual purpose within OMERACT. This hybrid group operates as a traditional working group focused on EDI initiatives and projects and is a strategic advisory body to the OMERACT Management Group. This distinctive structure enables the group to implement actionable EDI efforts and provide expert guidance to inform OMERACT's overarching policies and practices.

Through our dual role, we are committed to:

- Ensuring Diverse Participation
- Fostering Cultural Openness
- Supporting Inclusive Working Groups
- Expanding Global Collaborator Engagement
- Improving Accessibility and Inclusivity



Achievements 2024

- Transitioned to a hybrid working group/strategic advisory group structure while maintaining active initiatives.
- Expanded the fellowship program with two highly qualified members, strengthening expertise in health equity.
- Took significant steps to address barriers to participation through AI-powered translation tools and funding strategies.
- Enhanced external communication with targeted marketing to improve the perception of OMERACT's inclusivity.
- Initiated plans for educational content to increase awareness of EDI issues among members and collaborators.



Priorities 2025

- **2025 Conference Session Execution:** Finalize and deliver the planned "Comfy Couch" panel discussion and stakeholder-specific breakout sessions. Integrate survey insights into session discussions to ensure relevance and impact.
- **Broader Accessibility Efforts:** Pilot AI-powered translation tools during the Barcelona meeting and assess their effectiveness and feasibility. Continue addressing language and cultural barriers to participation across OMERACT initiatives.
- **Strategic Growth:** Explore additional funding models to increase accessibility for participants from LMICs and underrepresented groups. Strengthen collaborations with external EDI-focused organizations to enhance knowledge exchange and implementation.



Strategic Advisory Group



The OMERACT Strategic Advisory Group (SAG) serves as a key advisor to the OMERACT Management Group (MG), providing strategic advice on the overall direction and goals of OMERACT. The SAG comprises three co-chairs with expertise in areas relevant to OMERACT and several members chosen from relevant international collaborators. The areas of advice are distributed across four subcommittees: Governance, Meeting Organization, Education, and Branding.



Achievements 2024

- The SAG co-chairs met monthly (until July) to monitor the progress of the subcommittees' work.
- Throughout 2024, the SAG set key objectives for the year, and each subcommittee proposed a list of priorities.
- Subcommittee members successfully met online over the year to draft a list of recommendations to be discussed in a common workshop with the MG.
- The SAG co-chairs requested the MG to assess which recommendations should proceed to the next phase for further exploration and project planning, prioritizing each recommendation as high, medium, or low to ensure adequate resource allocation and alignment with OMERACT's strategic goals.
- During their review of the recommendations, the MG designated several initiatives as high priority, aligned with OMERACT's goals, and feasible for immediate focus (see minutes from the October SAG meeting). They requested more detailed implementation plans to guide which actions can realistically move forward, based on objective resource constraints.



Priorities 2025

- Evaluate the work of the first 2 years of SAG existence to adjust future work.
- Develop and implement potential action items that align with the MG's identified high-priority areas.
- Organize a SAG workshop to analyze feedback received on the proposed recommendations and brainstorm the SAG's role (Advisory vs. Management Responsibilities). SAG co-chairs will follow up with the MG to seek clarity on their expectations for the advisory group's role and determine the next steps.
- Support SIGs for and during the next OMERACT meeting to ensure they are aligned and prepared to deliver their work in a clear and standardized way.
- Analyze the results of accepted priorities on education and management after the 2025 OMERACT meeting.
- Continue collaboration with the MG to align strategies and clarify responsibilities.



OMERACT FELLOWS PROGRAM



The OMERACT Fellows program aims to provide a welcoming community for new OMERACT Fellows enabling inclusive participation prior, during and after the OMERACT meeting. The program includes education, mentoring, and collaboration opportunities.



Achievements 2024

- The 2023 Fellows and Program Chairs published an article titled “Evolving and evaluating the OMERACT fellows program: insights and implications from OMERACT 2023 fellows” in Seminars in Arthritis and Rheumatism in February 2024.
- Suzanne Verstappen and Caitlin Jones took over as co-chairs from the previous leadership team.



Priorities 2025

- Host a series of Fellows calls to prepare Fellows for the upcoming OMERACT 2025 meeting in Spain, including expectations and poster preparation.
- Run the in-person Fellows program at the 2025 meeting, which includes daily debriefings, collaborations with PRPs and Emerging Leaders, poster presentations, and lightning talks.



OMERACT EMERGING LEADERS PROGRAM



The Emerging Leaders Program focuses on providing early-career researchers, clinicians, and other collaborators with opportunities to engage with experienced mentors, gain exposure to OMERACT's work, and develop skills relevant to their careers.



Achievements 2024

- **Empowering Emerging Leaders:** Introduced a rotational leadership model to promote inclusivity and provide leadership opportunities for diverse participants.
- **Strengthening Learning and Operational Foundations:** Launched action learning sets and mentoring programs to enhance participants' practical leadership experience.



Priorities 2025

- **Advancing the ELP Curriculum and Leadership Model:** Finalize and implement the structured curriculum, including advanced methodology workshops and leadership training.
- **Expanding Support and Engagement:** Integrate ELP participants into broader OMERACT initiatives to enhance collaboration and cross-learning.



Working Group Co-Chairs

ANCA-Associated Vasculitis

Dr. Haner Direskeneli, Dr. Sarah Mackie, Dr. Peter Merkel & Dr. Gunnar Tómasson

Behçet's Syndrome

Dr. Haner Direskeneli, Dr. Gulen Hatemi & Dr. Peter Merkel

Calcium Pyrophosphate Deposition (CPPD)

Dr. Nicola Dalbeth, Dr. Sara Tedeschi & Dr. Abhishek Abhishek

Chronic Nonbacterial Osteomyelitis (CNO)

Dr. Philip Mease & Dr. Yongdong (Dan) Zhao

Composite Outcomes Working Group

Dr. Dorcas Beaton, Dr. Francis Guillemin, Dr. Sarah Mackie, Dr. Lyn March & Dr. George Wells

Contextual Factors

Dr. Robin Christensen, Dr. Lyn March & Dr. Peter Tugwell

Equity, Diversity & Inclusivity (EDI)

Dr. Jennifer Barton, Dr. Francis Guillemin, Grayson Schultz & Dr. Grace Wright

Flares in Osteoarthritis

Dr. Leigh Callahan, Dr. Francis Guillemin & Dr. Lyn March

Foot and Ankle Disorders

Dr. Marian Hannan, Dr. Phillip Helliwell, Dr. Hylton Menz & Dr. Heidi Siddle

Glucocorticoid-Related Adverse Events

Dr. Susan Goodman, Dr. Catherine Hill, Dr. Sarah Mackie & Dr. Joanna Robson

Gout

Dr. Robin Christensen, Dr. Jasvinder Singh & Dr. Lisa Stamp

Juvenile Idiopathic Arthritis (JIA)

Dr. Alessandro Consolaro, Dr. Esi Morgan & Dr. Jane Munro

Large Vessel Vasculitis

Dr. Sibel Aydin, Dr. Haner Direskeneli, Dr. Sarah Mackie & Dr. Peter Merkel

Late-stage Knee and Hip Osteoarthritis

Dr. Francis Guillemin, Dr. Gillian Hawker, Dr. David Hunter & Dr. Lyn March

Magnetic Resonance Imaging (MRI) Taskforce

Dr. Paul Bird, Dr. Philip Conaghan, Dr. Mikkel Ostergaard & Dr. Charles Peterfy

Myositis

Dr. Helene Alexanderson, Dr. Jin Park, Dr. Chris Mecoli & Dr. Lisa Christopher-Stine

Pain

Dr. Ernest Choy, Dr. Philip Mease & Dr. Lee Simon

Patient Outcomes in Longitudinal Studies in RA (POLOS-RA)

Dr. Loreto Carmona, Dr. Catherine Hill & Dr. Maria Suarez-Almazor

Patient Preferences to Value Health Outcomes in Rheumatology Clinical Trials (PPRCTs)

Dr. Nick Bansback, Dr. Annelies Boonen, Dr. Rachelle Buchbinder, Dr. Liana Fraenkel & Dr. Glen Hazlewood

Polymyalgia Rheumatica (PMR)

Dr. Thomas Bolhuis, Dr. Catherine Hill, Dr. Sarah Mackie, Dr. Claire Owen, Dr. Sebastian Sattui, Dr. Lee Simon & Dr. Max Yates

Psoriatic Arthritis (PsA)

Dr. Dafna Gladman, Dr. Katy Leung, Dr. Ana-Maria Orbai & Dr. William Tillett

Remission in RA-Patient Perspective

Dr. Caroline Flurey, Dr. Susanna Proudman & Dr. Peter Tugwell

Safety

Dr. Peter Brooks, Dr. Robin Christensen, Dr. Caroline Flurey & Dr. Lee Simon

Scleroderma Vascular Disease

Dr. Ariane Herrick, Dr. Peter Merkel, Dr. John Pauling & Dr. Susanna Proudman

Shared Decision Making (SDM)

Dr. Jennifer Barton, Dr. Peter Brooks, Dr. Simon Décary, Dr. Liana Fraenkel, Dr. Linda Li, Dr. Alexa Meara & Dr. Karine Toupin April

Shoulder Disorders

Dr. Rachelle Buchbinder, Dr. Joel Gagnier, Dr. Sofia Ramiro, Dr. Arianne Verhagen & Dr. Sam Whittle

Sjögren's Disease

Dr. Sara McCoy, Dr. Raphaèle Seror, Dr. Simon Bowman & Dr. Maureen Rischmueller

Synovial Tissues in RCT

Dr. Aurelie Najm, Dr. Mihir Wechalekar & Dr. Vibeke Strand

Systemic Lupus Erythematosus (SLE)

Dr. Lee Simon, Dr. Vibeke Strand & Dr. Zahi Touma

Ultrasound


Dr. Peter Mandl, Dr. Helen Keen, Dr. Carlos Pineda & Dr. Maria Antonietta D'Agostino

Worker Productivity

Dr. Reuben Escorpizo, Dr. Diane Lacaille & Dr. Suzanne Verstappen

Working Group Support Summary


Throughout the year, the OMERACT Working Group (WG) Liaison has provided support to multiple working groups, ensuring progress, adherence to OMERACT methods, and alignment with research goals. This summary highlights the value and impact of the liaison's contributions, in addition to the support provided by the OMERACT Handbook Group and the OMERACT Technical Advisory Group.



The liaison role has proven invaluable in facilitating the progress of working groups. The liaison support ensures that groups maintain focus on their goals, adhere to OMERACT methods, and receive timely feedback and guidance. This support has driven key milestones, particularly in domain and instrument selection, ensuring that methods protocols, qualitative work, and instrument selection align with OMERACT guidelines.

This liaison support helps OMERACT Working Groups maintain a high standard of research rigour, advancing Core Outcome Sets that are patient-centered and methodologically sound. The continuous involvement of a dedicated liaison demonstrates a commitment to fostering collaborative research environments and achieving meaningful results in rheumatology and musculoskeletal health research.

WORKING GROUPS' PROGRESS TOWARDS THE DEVELOPMENT OF A CORE OUTCOME SET - DOMAINS



WORKING GROUPS' PROGRESS TOWARDS THE DEVELOPMENT OF A CORE OUTCOME SET - INSTRUMENTS

REVIEW DEFINITION & DECIDE ON METHODS

Behçet's Syndrome

Glucocorticoids

JIA

Large Vessel Vasculitis

Pain

DOMAIN MATCH

NARROW THE FIELD

INSTRUMENT RATIFICATION

SELECT INSTRUMENT

Shared Decision Making

Safety

FEASIBILITY

GATHER THE EVIDENCE

Myositis


Polymyalgia Rheumatica (PMR)

Shoulder Disorders

Worker Productivity

CORE OUTCOME SET ENDORSEMENT

WORKING GROUPS' PROGRESS TOWARDS THE DEVELOPMENT OF A CORE OUTCOME SET - INSTRUMENTS




2024 Publications

SEMINARS IN
ARTHRITIS & RHEUMATISM

OMERACT is proud to partner with Seminars in Arthritis and Rheumatism to support the publication efforts of our working groups. In 2024, this partnership contributed to an impressive **36 OMERACT publications**, highlighting our collective dedication to advancing research. With a CiteScore of 9.1 and an Impact Factor of 5.431, Seminars in Arthritis and Rheumatism delivers high-quality research on arthritis, rheumatology, and musculoskeletal disorders. Published bimonthly, the journal features diagnostic criteria, consensus statements, systematic reviews, meta-analyses, and clinical studies, offering valuable insights to rheumatologists, internal medicine physicians, immunologists, and bone specialists. This collaboration strengthens OMERACT's mission to disseminate research and improve health outcomes globally.

Publications by Type



OMERACT Priorities for 2025

1

SUCCESSFUL OMERACT 2025 IN-PERSON CONFERENCE

Prepare for and ensure the success of the OMERACT 2025 conference.

- Key Actions:
 - Finalize the conference programming, including plenary sessions, special interest group (SIG) sessions.
 - Strengthen outreach to ensure diverse participation, including researchers, clinicians, and attendees from low- and middle-income countries (LMICs).

2

VALIDATION OF INSTRUMENTS FOR FOUR FOUNDATIONAL DOMAINS FOUND IN OMERACT CORE OUTCOME SETS

Complete and present the Summary of Measurement Property(SOMP) tables for pain intensity, pain interference, physical function, and fatigue for use in Core Outcome Sets.

- Key Actions:
 - Ratification of findings at OMERACT 2025
 - Publish findings in peer-reviewed journals to ensure widespread dissemination and transparency.

3

PUBLICATION OF A SERIES OF GUIDELINES PAPERS FURTHER ESTABLISHING OMERACT AS A LEADER IN CORE OUTCOME SET DEVELOPMENT

Solidify OMERACT's position as a global leader by providing comprehensive guidance on core outcome set development and implementation.

- Key Actions:
 - Publish a series of papers on topics such as patient engagement, domain generation, instrument selection, and equity, diversity, and inclusion (EDI) in outcomes research.
 - Collaborate with international organizations to disseminate guidelines widely.


4

PUBLICATION OF THE OMERACT HANDBOOK


Release the updated OMERACT Handbook as a definitive resource for researchers and working groups.

- Key Actions:
 - Finalize revisions to include recent advances in methodologies, PRP engagement, and EDI considerations.
 - Develop an online companion to the handbook for easier access and updates.
 - Organize virtual training sessions to familiarize stakeholders with the handbook's content and applications.

2024 Expenditure Summary



OMERACT 2025 Conference Budget



2024 Sponsor Support

Platinum

abbvie

Janssen
PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

NOVARTIS

Silver

Pfizer

Bronze

CENTREXION
THERAPEUTICS

sparrow
PHARMACEUTICALS

Special Projects & Directed Working Group Support

abbvie

Bristol Myers Squibb

EMD
SERONO

Janssen
PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

NOVARTIS



OMERACT 2025 MAY 14- MAY 18



**SAVE
THE
DATE**

**ADVANCING
CORE OUTCOME
SETS IN
RHEUMATOLOGY
THROUGH
COLLABORATION**

**TERRASSA,
BARCELONA,
SPAIN**

LEARN MORE



**FOR MORE INFORMATION, CONTACT OMERACT AT
ADMIN@OMERACT.ORG**

multumesc

اركش

thank y

dankie

gratias ago

es

We extend our gratitude to the
OMERACT community and
members of the Business
Advisory Committee for their
invaluable contributions to
OMERACT



Contact Us:

(613) 794-1355 ▪ admin@omeract.org

www.omeract.org